Caladrius Biosciences Inc (CLBS) Expected to Post Earnings of -$0.38 Per Share

Brokerages expect Caladrius Biosciences Inc (NASDAQ:CLBS) to report earnings per share (EPS) of ($0.38) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences reported earnings of ($0.40) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 5%. The firm is expected to announce its next earnings results on Thursday, March 28th.

On average, analysts expect that Caladrius Biosciences will report full year earnings of ($1.75) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($1.69). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.03) per share, with EPS estimates ranging from ($2.36) to ($1.69). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Caladrius Biosciences.

Caladrius Biosciences (NASDAQ:CLBS) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.36) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.56) by $0.20.



Several analysts have recently weighed in on CLBS shares. HC Wainwright started coverage on shares of Caladrius Biosciences in a research report on Tuesday, November 20th. They set a “buy” rating and a $18.50 price objective on the stock. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $5.50 price objective on the stock in a research report on Monday, November 19th.

Caladrius Biosciences stock opened at $4.84 on Friday. The firm has a market cap of $48.32 million, a PE ratio of -2.72 and a beta of 1.44. Caladrius Biosciences has a fifty-two week low of $3.05 and a fifty-two week high of $11.65.

A hedge fund recently raised its stake in Caladrius Biosciences stock. Vanguard Group Inc grew its stake in shares of Caladrius Biosciences Inc (NASDAQ:CLBS) by 2.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 202,568 shares of the biotechnology company’s stock after buying an additional 5,700 shares during the quarter. Vanguard Group Inc owned 2.06% of Caladrius Biosciences worth $1,196,000 at the end of the most recent quarter. Institutional investors and hedge funds own 7.74% of the company’s stock.

About Caladrius Biosciences

Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Featured Story: How Do I Invest in Dividend Stocks

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply